4 Results for "

ADME prediction

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "ADME prediction" in MCE Product Catalog:

Cat. No.: HY-147027
CAS No.: 684234-55-7
Purity:  99.48%
PARP-1-IN-2 (compound 11g) is a potent PARP1 inhibitor, with an IC50 of 149 nM, and ADME prediction indicates it has high blood-brain barrier permeability. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .
loading...
    loading...
Cat. No.: HY-163415
CAS No.: 906728-07-2
Target:  

Monoamine Oxidase

Research Areas:  

Neurological Disease

MAO-IN-5 (Compound ZINC000016952895) is a monoamine oxidase (MAO) inhibitor. According to the prediction of Swiss ADME, MAO-IN-5 can inhibit the CYP enzyme family, has blood-brain barrier (BBB) permeability, and has a high gastrointestinal absorption rate. MAO-IN-5 can be used in the study of neurological diseases .
loading...
    loading...
Cat. No.: HY-147919
CAS No.: 2445277-57-4
Target:  

Fungal

Research Areas:  

Infection

Antifungal agent 33 (compound 4e) is a potent antifungal agent. Antifungal agent 33 exhibits remarkable antifungal activity against C. albicans, with a MIC of 16 μg/mL. Antifungal agent 33 shows potent inhibitory activity against Lanosterol 14α-demethylase (CYP51), with an IC50 of 0.19 μg/mL .
loading...
    loading...
Cat. No.: HY-175245
Target:  

Carbonic Anhydrase

Research Areas:  

Cancer

hCA-IN-1 (Compound 5u) is an hCA inhibitor with Ki values of 159.2, 4.8, 15.5, and 2 nM against hCA I, hCA II, hCA IX, and hCA XII, respectively. hCA-IN-1 exhibits broad-spectrum anticancer activity against melanoma, breast, and colon cancer cells. ADME predictions indicate that hCA-IN-1 has good solubility and oral bioavailability. hCA-IN-1 can be used in tumor research .
loading...
    loading...